- Ohta, Toshiharu; Komoriya, Satoshi; Yoshino, Toshiharu; Uoto, Kouichi; Nakamoto, Yumi; Naito, Hiroyuki; Mochizuki, Akiyoshi; Nagata, Tsutomu; Kanno, Hideyuki; Haginoya, Noriyasu; et al, Diamine Derivatives, Daiichi Pharmaceutical Co., Ltd., Japan, EP1405852B1, August 1, 2012
- He, Ling; Kochan, Jarema; Lin, Min; Vandell, Alexander; Brown, Karen; Depasse, Francois, Determination of edoxaban equivalent concentrations in human plasma by an automated anti-factor Xa chromogenic assay, Thrombosis Research, Volume: 155,Pages: 121-127, 2017
Frequently Asked Questions
Edoxaban impurities identification involves various analytical techniques such as spectroscopy, chromatography, and mass spectrometry. These methods help determine the chemical structure and composition of impurities.
Yes, impurities in Edoxaban are closely monitored during clinical trials to assess their impact on safety, efficacy, and patient tolerability. Any significant impurities are thoroughly evaluated and controlled.
Certain impurities in Edoxaban may have the potential to interact with other medications. Drug-drug interaction studies help evaluate such possibilities and ensure safe co-administration.
Storage conditions can influence the formation of impurities in Edoxaban. Proper storage, including temperature control and protection from light and moisture, is essential to minimize impurity formation.
Edoxaban impurities are stored at a controlled room temperature between 2-8 °C or as indicated on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.